Advanced search
Publication Cover
Expert Opinion on Investigational Drugs Volume 29, 2020 - Issue 10
Submit an article Journal homepage
4,014
Views
14
CrossRef citations to date
0
Altmetric
DRUG EVALUATION

Melflufen for relapsed and refractory multiple myeloma

Albert Oriola Institut Josep Carreras and Institut Català d’Oncologia, Hospital Germans Trias I Pujol, Badalona, SpainView further author information
,
Alessandra Laroccab Azienda Ospedaliero-Universitaria Città Della Salute E Della Scienza Di Torino, University of Torino, Torino, ItalyView further author information
,
Xavier Leleuc Department of Hematology, Hôpital De La Milétrie, CHU De Poitiers, Poitiers, FranceORCID Iconhttps://orcid.org/0000-0002-9822-4170View further author information
ORCID Icon,
Roman Hajekd Department of Hemato-Oncology, University of Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech RepublicView further author information
,
Hani Hassoune Myeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USAView further author information
,
Paula Rodríguez-Oterof Department of Hematology, Clínica Universidad De Navarra, Pamplona, SpainView further author information
,
Agne Panerg Division of Hematology, Oncology and Stem Cell Transplant, Rush University Medical Center, Chicago, IL, USAView further author information
,
Fredrik H. Schjesvoldh Oslo Myeloma Center, Oslo University Hospital and K.G. Jebsen Centre for B-Cell Malignancies, University of Oslo, Oslo, NorwayView further author information
,
Joachim Gullboi Department of Medical Sciences, Division of Clinical Pharmacology, Uppsala University, Uppsala, SwedenView further author information
&
Paul G. Richardsonj Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USACorrespondence[email protected]
View further author information
 show all
Pages 1069-1078 | Received 16 Jun 2020, Accepted 08 Aug 2020, Published online: 29 Sep 2020

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Massimo Offidani, Laura Corvatta, Sonia Morè & Attilio Olivieri. (2021) Novel Experimental Drugs for Treatment of Multiple Myeloma. Journal of Experimental Pharmacology 13, pages 245-264.
Read now

Articles from other publishers (13)

Ulrica Westermark, Yumei Diao, Karl-Johan Fasth, Mathias Färnegårdh, Katarina Färnegårdh, Kristin Hammer, Fredrik Lehmann, Klara Acs & Stefan Svensson Gelius. (2023) A rapid intracellular enrichment of alkylating payload is essential for melphalan flufenamide potency and mechanism of action. Biochemical and Biophysical Research Communications 656, pages 122-130.
Crossref
Lamees Al Kayyali, Zaid Abu Diak, Osama Abu Diak & Janusz Krawczyk. 2023. Recent Updates on Multiple Myeloma. Recent Updates on Multiple Myeloma.
Chen Fu, Lifeng Yu, Yuxi Miao, Xinli Liu, Zhaojin Yu & Minjie Wei. (2023) Peptide–drug conjugates (PDCs): a novel trend of research and development on targeted therapy, hype or hope?. Acta Pharmaceutica Sinica B 13:2, pages 498-516.
Crossref
Xinyan Jia, Xiangxin Liu & Wenzhong Yang. (2022) Predictive Value Analysis of Serum Ig A, Ig G, and TNF-α in Recurrence of Multiple Myeloma. Disease Markers 2022, pages 1-7.
Crossref
Archna Panghal, Chittaranjan Sahu, Shivani Singla & Gopabandhu Jena. (2022) Juvenile exposure and adult risk assessment with single versus repeated exposure of melphalan in the germ cells of male SD rat: Deciphering the molecular mechanisms. Reproductive Toxicology 113, pages 71-84.
Crossref
Rakesh Pahwa, Jatin Chhabra, Raj Kumar & Rakesh Narang. (2022) Melphalan: Recent insights on synthetic, analytical and medicinal aspects. European Journal of Medicinal Chemistry 238, pages 114494.
Crossref
Martin S. Highley, Bart Landuyt, Hans Prenen, Peter G. Harper & Ernst A. De Bruijn. (2022) The Nitrogen Mustards. Pharmacological Reviews 74:3, pages 552-599.
Crossref
Seong-Bin Yang, Nipa Banik, Bomin Han, Dong-Nyeong Lee & Jooho Park. (2022) Peptide-Based Bioconjugates and Therapeutics for Targeted Anticancer Therapy. Pharmaceutics 14:7, pages 1378.
Crossref
Ken Flanagan, Romika Kumari, Juho J. Miettinen, Staci L. Haney, Michelle L. Varney, Jacob T. Williams, Muntasir M. Majumder, Minna Suvela, Ana Slipicevic, Fredrik Lehmann, Nina N. Nupponen, Sarah A. Holstein & Caroline A. Heckman. (2022) The Peptide–Drug Conjugate Melflufen Modulates the Unfolded Protein Response of Multiple Myeloma and Amyloidogenic Plasma Cells and Induces Cell Death. HemaSphere 6:3, pages e687.
Crossref
Anastazja Poczta, Piotr Krzeczyński, Joanna Tobiasz, Aneta Rogalska, Arkadiusz Gajek & Agnieszka Marczak. (2022) Synthesis and In Vitro Activity of Novel Melphalan Analogs in Hematological Malignancy Cells. International Journal of Molecular Sciences 23:3, pages 1760.
Crossref
Mohamed Elemary & Ibraheem Othman. 2022. Paraproteinemia and Related Disorders. Paraproteinemia and Related Disorders 355 376 .
Mingming Zhang, Linghui Zhou, Houli Zhao, Yanlei Zhang, Guoqing Wei, Ruimin Hong, Wenjun Wu, Huijun Xu, Linqin Wang, Fang Ni, Jiazhen Cui, Shuixiu Peng, Chih-Hua Huang, Alex H. Chang, Yongxian Hu & He Huang. (2021) Risk Factors Associated with Durable Progression-Free Survival in Patients with Relapsed or Refractory Multiple Myeloma Treated with Anti-BCMA CAR T-cell Therapy. Clinical Cancer Research 27:23, pages 6384-6392.
Crossref
Konstantin Byrgazov, Andrej Besse, Marianne Kraus, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen & Lenka Besse. (2021) Novel Peptide-drug Conjugate Melflufen Efficiently Eradicates Bortezomib-resistant Multiple Myeloma Cells Including Tumor-initiating Myeloma Progenitor Cells. HemaSphere 5:7, pages e602.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.